MEDICAMEQ

Medicamen Biotech Limited

Formulations and healthcare products manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

medicamen.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹284.45
Market cap
386 Cr
Stock P/E
35.6
P/B
1.40
Dividend yield
0.4%
ROE (FY26)
3.5%
ROCE (FY26)
4.8%
Operating margin (FY26)
6.3%
Debt / equity (FY26)
0.17
OCF / EBITDA (FY26)
-169.4%
OCF / EBITDA (3Y)
-73.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Medicamen Biotech makes and sells pharmaceutical formulations, mainly through wholesale drug distributors and stockists, and sells across more than 35 countries.

Company snapshot

101stBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.17x — the company is largely funded by its own money, not borrowed funds.
Concerns
  • ✗Over the last three years operations used more cash than they brought in, despite an operating profit — the business is not yet turning its profit into cash.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales44 Cr47 Cr47 Cr43 Cr45 Cr45 Cr30 Cr43 Cr47 Cr47 Cr61 Cr48 Cr
Operating expenses (approx.)39 Cr42 Cr42 Cr40 Cr39 Cr38 Cr31 Cr38 Cr42 Cr43 Cr55 Cr44 Cr
EBITDA5 Cr5 Cr6 Cr3 Cr5 Cr7 Cr-2 Cr5 Cr5 Cr4 Cr5 Cr4 Cr
OPM %10.7%10.5%12.2%8.0%11.9%14.9%-5.4%10.7%10.9%9.3%9.0%9.0%
Other income0.55 Cr0.83 Cr0.57 Cr0.59 Cr0.29 Cr0.14 Cr5 Cr0.47 Cr0.37 Cr0.53 Cr2 Cr0.86 Cr
Interest0.91 Cr0.65 Cr2 Cr0.71 Cr1 Cr0.76 Cr0.65 Cr1 Cr0.99 Cr0.97 Cr0.38 Cr0.83 Cr
Depreciation2 Cr2 Cr2 Cr2 Cr3 Cr2 Cr0.48 Cr2 Cr2 Cr2 Cr2 Cr2 Cr
Profit before tax2 Cr3 Cr3 Cr2 Cr2 Cr4 Cr2 Cr2 Cr3 Cr2 Cr5 Cr3 Cr
Tax %40.1%38.0%23.2%48.7%53.8%24.6%25.2%24.9%21.2%22.6%12.1%28.2%
Net profit1 Cr2 Cr2 Cr0.80 Cr0.90 Cr3 Cr2 Cr2 Cr2 Cr2 Cr4 Cr2 Cr
EPS (₹)₹1.17₹1.60₹1.61₹0.63₹0.71₹2.30₹1.47₹1.18₹1.56₹1.21₹3.28₹1.36

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales126 Cr113 Cr115 Cr141 Cr179 Cr163 Cr198 CrSign in free for the trailing twelve months
Operating expenses (approx.)106 Cr93 Cr92 Cr117 Cr157 Cr149 Cr178 CrSign in free for the trailing twelve months
EBITDA19 Cr19 Cr24 Cr24 Cr22 Cr14 Cr20 CrSign in free for the trailing twelve months
OPM %15.2%17.1%20.4%16.9%12.4%8.5%9.9%Sign in free for the trailing twelve months
Other income2 Cr0.75 Cr2 Cr2 Cr2 Cr6 Cr3 CrSign in free for the trailing twelve months
Interest0.57 Cr1 Cr1 Cr3 Cr4 Cr3 Cr3 CrSign in free for the trailing twelve months
Depreciation2 Cr3 Cr6 Cr6 Cr7 Cr7 Cr7 CrSign in free for the trailing twelve months
Profit before tax18 Cr16 Cr18 Cr17 Cr13 Cr10 Cr12 CrSign in free for the trailing twelve months
Tax %26.1%26.0%17.7%13.6%27.4%33.6%18.3%Sign in free for the trailing twelve months
Net profit13 Cr12 Cr15 Cr15 Cr9 Cr7 Cr10 CrSign in free for the trailing twelve months
EPS (₹)₹10.94₹9.93₹12.19₹11.82₹7.50₹5.16₹7.22Sign in free for the trailing twelve months
Dividend payout %—5.0%8.2%8.6%13.3%19.4%13.8%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital12 Cr12 Cr12 Cr13 Cr13 Cr13 Cr14 Cr
Reserves109 Cr121 Cr134 Cr181 Cr188 Cr200 Cr262 Cr
Borrowings10 Cr17 Cr24 Cr24 Cr31 Cr33 Cr48 Cr
Other liabilities50 Cr44 Cr55 Cr61 Cr63 Cr51 Cr49 Cr
Total liabilities181 Cr194 Cr226 Cr279 Cr295 Cr297 Cr372 Cr
Fixed assets (net)33 Cr89 Cr92 Cr92 Cr91 Cr86 Cr84 Cr
CWIP40 Cr—0 Cr————
Investments0 Cr53 Cr0 Cr0 Cr0 Cr0 Cr0 Cr
Loans & advances9 Cr0 Cr5 Cr7 Cr4 Cr3 Cr38 Cr
Inventories17 Cr5 Cr27 Cr45 Cr59 Cr62 Cr70 Cr
Trade receivables50 Cr4 Cr63 Cr65 Cr55 Cr69 Cr82 Cr
Cash & bank3 Cr7 Cr0 Cr21 Cr15 Cr4 Cr31 Cr
Other assets29 Cr36 Cr38 Cr49 Cr70 Cr73 Cr67 Cr
Total assets181 Cr194 Cr226 Cr279 Cr295 Cr297 Cr372 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity13 Cr13 Cr4 Cr-6 Cr-0.37 Cr-7 Cr-33 Cr
Cash from investing-37 Cr-18 Cr-8 Cr-6 Cr-6 Cr-2 Cr-3 Cr
Cash from financing19 Cr6 Cr4 Cr29 Cr-0.06 Cr-2 Cr64 Cr
Net cash flow-5 Cr0.80 Cr-0.07 Cr17 Cr-6 Cr-11 Cr28 Cr
Free cash flow (OCF − Capex)-25 Cr-5 Cr-4 Cr-13 Cr-7 Cr-9 Cr-38 Cr

Ratios

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %14.1%11.6%11.4%9.2%7.6%5.3%4.8%
ROE %11.0%9.1%10.2%7.7%5.5%3.3%3.5%
Debtor days14513199169112154151
Inventory days7728177200207250270
Days payable170171283212158171154
Cash conversion cycle53-13193157161233267
OCF / EBITDA %67.0%66.4%17.5%-26.4%-1.6%-51.9%-169.4%
OCF / EBITDA % (3 years)——48.0%15.9%-3.7%-23.1%-73.1%
Debt / equity0.080.130.170.130.150.160.17
Current ratio1.841.801.691.981.752.112.54
Net debt / EBITDA0.360.531.030.140.722.130.84